Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07:46 | Einmalige Chance: Nach Milliarden-Deal - Übernahme-Karussell nimmt Fahrt auf! | Hotstock Investor | |||
07:24 | Arvinas gets new chief medical head | 1 | Seeking Alpha | ||
07:10 | ObsEva SA: ObsEva Announces Update on Board of Directors | 105 | GlobeNewswire (Europe) | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland - March 18, 2024 - ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing... ► Artikel lesen | |
07:06 | Innate Pharma SA: Innate Pharma Announces Its Participation to Upcoming Investor Conference | 112 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming... ► Artikel lesen | |
07:06 | Nykode Therapeutics ASA: Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases | 1 | GlobeNewswire (USA) | ||
05:10 | Jetzt aufpassen - 100 % Performance möglich mit BioNTech, Bayer, Cardiol Therapeutics oder HelloFresh | 487 | inv3st.de | Für Investoren im BioTech-Sektor startet das Jahr 2024, wie das vorherige geendet hat. Man wartet auf den Big Bang, der sich noch nicht so recht einstellen möchte. Doch wo es keine Pandemie mehr gibt... ► Artikel lesen | |
04:17 | Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST | 19 | CNW | ||
02:59 | Innovent: Phase 2 Trial Of IBI302 In Neovascular Age-related Macular Degeneration Meets Main Goal | - | RTTNews | ||
02:35 | Are CSL shares a must-buy in March? | 2 | The Motley Fool Australia | ||
02:30 | Novo Holdings sells shares in Spruce Biosciences worth over $1.6 million | 1 | Investing.com | ||
02:06 | Arcellx CFO sells over $470k in company stock | 1 | Investing.com | ||
01:50 | OPTHEA LIMITED: Opthea to Host Key Opinion Leader Event on April 3, 2024 | - | ASX | ||
00:42 | Earnings call: Biofrontera posts record revenue and outlines growth plans | 7 | Investing.com | ||
00:30 | Harmony Biosciences exec sells over $383k in stock | 1 | Investing.com | ||
00:30 | Earnings call: Acurx Pharmaceuticals Reports Positive Phase IIb Results | 2 | Investing.com | ||
00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 19.03.2024 | 14 | Xetra Newsboard | The following instruments on XETRA do have their first trading 19.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 19.03.2024
Aktien
1 US74738N2027 QSAM Biosciences Inc.
Anleihen
1... ► Artikel lesen | |
Mo | Briacell Therapeutics Corp reports results for the quarter ended in January - Earnings Summary | 1 | Reuters | ||
Mo | Arcellx director Ware sells over $630k in company stock | 1 | Investing.com | ||
Mo | Why Bluebird Bio Stock Flew Higher Than the Market Today | 1 | The Motley Fool | ||
Mo | Cormorant Asset Management sells over $2.7 million in Immuneering Corp shares | 1 | Investing.com |
Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
---|---|---|---|---|---|---|---|
MORPHOSYS | 8 | 58 | 0,00 % | Pharmakonzern Novartis darf Morphosys übernehmen | BONN/BASEL (dpa-AFX) - Der Schweizer Pharmakonzern Novartis darf das bayerische Biotech-Unternehmen Morphosys übernehmen. Das Bundeskartellamt gab am Dienstag die Freigabe der Transaktion bekannt.... ► Artikel lesen | ||
TANGO THERAPEUTICS | 8 | 8 | -6,20 % | Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights | BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines... ► Artikel lesen | ||
BIONTECH | 7 | 35 | +0,42 % | BioNTech meldet sich zurück: Zwei wichtige Termine vormerken | Die Aktie von BioNTech hat zum Wochenstart ein klares Lebenszeichen von sich gegeben. Mehr als fünf Prozent konnte das Papier am Montag zulegen, nachdem die Mainzer angekündigt haben, auf der bevorstehenden... ► Artikel lesen | ||
KARUNA THERAPEUTICS | 7 | 11 | +0,00 % | Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) has successfully completed its acquisition of Karuna Therapeutics, Inc. Karuna shares have ceased trading on the Nasdaq Global Select Market... ► Artikel lesen | ||
LEAP THERAPEUTICS | 7 | 7 | +5,05 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results | CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial... ► Artikel lesen | ||
SINGULAR GENOMICS SYSTEMS | 7 | 7 | +7,80 % | Singular Genomics Systems Inc reports results for the quarter ended in December - Earnings Summary | |||
FARON PHARMACEUTICALS | 6 | 12 | 0,00 % | Faron Pharmaceuticals Oy: Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML | Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR HMA-failed MDS patients... ► Artikel lesen | ||
ACURX PHARMACEUTICALS | 6 | 9 | -1,53 % | Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update | STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class... ► Artikel lesen | ||
BLUEBIRD BIO | 6 | 7 | -1,34 % | Why Bluebird Bio Stock Flew Higher Than the Market Today | |||
TENAYA THERAPEUTICS | 6 | 6 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine | TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart... ► Artikel lesen |
Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
---|---|---|---|---|---|---|---|---|---|
BIO-GATE AG | 1,130 | 4,20 | +272 % | 1 | - | - | |||
EVOTEC SE | 13,145 | 22,90 | +74 % | 6 | 5 | - | |||
QIAGEN NV | 40,620 | 50,60 | +25 % | 9 | 5 | - | |||
SARTORIUS STEDIM BIOTECH SA | 276,50 | 330 | +19 % | 1 | - | - | |||
MODERNA INC | 96,14 | 114,04 | +19 % | 1 | - | - | |||
BIONTECH SE ADR | 85,30 | 100,56 | +18 % | - | 1 | - | |||
MORPHOSYS AG | 66,40 | 41,33 | -38 % | 9 | 3 | - |